|
Volumn 16, Issue 7, 2010, Pages 740-743
|
The inverse of immunity
a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIBODY;
AUTOANTIBODY;
CYANAMIDE;
DIRUCOTIDE;
DNA VACCINE;
ETHYLENE CARBODIIMIDE;
IMMUNOSUPPRESSIVE AGENT;
INTERLEUKIN 4;
MYELIN ASSOCIATED GLYCOPROTEIN;
MYELIN BASIC PROTEIN;
MYELIN BASIC PROTEIN[82-98];
MYELIN OLIGODENDROCYTE GLYCOPROTEIN;
PEPTIDE FRAGMENT;
PLACEBO;
PROTEOLIPID PROTEIN;
SMALLPOX VACCINE;
TOVAXIN;
UNCLASSIFIED DRUG;
VACCINE;
ANTIGEN SPECIFICITY;
AUTOIMMUNE DISEASE;
AUTOIMMUNITY;
CLINICAL TRIAL;
DISEASE COURSE;
DNA IMMUNIZATION;
HUMAN;
IMMUNE SYSTEM;
IMMUNIZATION;
IMMUNOSUPPRESSIVE TREATMENT;
MULTIPLE SCLEROSIS;
NONHUMAN;
NOTE;
PRIORITY JOURNAL;
RELAPSE;
VACCINATION;
ANIMALS;
AUTOIMMUNE DISEASES;
CLINICAL TRIALS AS TOPIC;
COMPASSIONATE USE TRIALS;
HUMANS;
IMMUNE TOLERANCE;
INDIVIDUALIZED MEDICINE;
MICE;
MULTIPLE SCLEROSIS;
VACCINES;
VACCINES, DNA;
VACCINES, SUBUNIT;
|
EID: 77954493155
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm0710-740 Document Type: Note |
Times cited : (18)
|
References (12)
|